MICRAININ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MICRAININ (MICRAININ).
MICRAININ is a combination of acetaminophen (paracetamol) and butalbital. Acetaminophen inhibits cyclooxygenase (COX) enzymes in the central nervous system, reducing prostaglandin synthesis and modulating pain perception via activation of descending serotonergic pathways. Butalbital is a barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and causing central nervous system depression.
| Metabolism | Acetaminophen is primarily metabolized in the liver via glucuronidation and sulfation; a minor pathway via CYP2E1 and CYP3A4 produces the toxic metabolite NAPQI. Butalbital is extensively metabolized by CYP2C19 and other hepatic enzymes. |
| Excretion | Primarily renal (70% unchanged, 20% as sulfate conjugate); biliary/fecal <10% |
| Half-life | Terminal elimination half-life 8-12 hours; in elderly or severe renal impairment, may extend to 24 hours |
| Protein binding | 70-80% bound to albumin |
| Volume of Distribution | 0.3-0.5 L/kg; indicates moderate distribution into total body water |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism); Intramuscular: 75-85%; Intravenous: 100% |
| Onset of Action | Oral: 30-60 minutes; Intravenous: 5-10 minutes; Intramuscular: 15-30 minutes |
| Duration of Action | 4-6 hours; may be prolonged in hepatic or renal impairment (up to 8-12 hours) |
2 tablets orally at onset of migraine, then 1 tablet every 1-2 hours as needed, up to 4 tablets per attack, not to exceed 6 tablets per day. Each tablet contains isometheptene mucate 65 mg, dichloralphenazone 100 mg, and acetaminophen 325 mg.
| Dosage form | TABLET |
| Renal impairment | Not studied; use caution with CrCl <30 mL/min. Avoid if severe renal impairment (CrCl <15 mL/min) due to acetaminophen and dichloralphenazone accumulation. No specific dose adjustment guidelines available. |
| Liver impairment | Contraindicated in severe hepatic impairment (Child-Pugh C). In moderate impairment (Child-Pugh B), reduce dose by 50% or increase dosing interval. In mild impairment (Child-Pugh A), no adjustment necessary but monitor. |
| Pediatric use | Not recommended for pediatric patients due to lack of safety and efficacy data; alternative agents preferred. |
| Geriatric use | Use with caution due to increased sensitivity to anticholinergic effects, sedation, and hepatotoxicity. Initiate at lower doses (e.g., 1 tablet at onset) and titrate slowly. Monitor renal and hepatic function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for MICRAININ (MICRAININ).
| Breastfeeding | Butalbital is excreted into breast milk; the milk-to-plasma ratio is approximately 0.3-0.6. Infants are at risk of sedation, poor feeding, and withdrawal. Acetaminophen is excreted in low amounts (M/P ~0.2-0.9) and is considered compatible. Caffeine is excreted in breast milk (M/P ~0.5) and may cause irritability in infants. Use of MICRAININ during breastfeeding is generally not recommended due to butalbital. |
| Teratogenic Risk | MICRAININ is a combination of butalbital, acetaminophen, and caffeine. Butalbital is a barbiturate; barbiturates are associated with increased risk of congenital malformations, particularly neural tube defects, when used in the first trimester. Chronic use in the third trimester can lead to neonatal withdrawal syndrome and floppy infant syndrome. Acetaminophen is generally considered low risk at therapeutic doses. Caffeine in moderate amounts is not strongly associated with major malformations, but high doses may increase risk of miscarriage. |
■ FDA Black Box Warning
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed 4000 mg per day, and often involve more than one acetaminophen-containing product.
| Serious Effects |
Hypersensitivity to acetaminophen, butalbital, or any component; porphyria; severe hepatic impairment; history of barbiturate dependence.
| Precautions | Hepatotoxicity: Severe liver injury may occur with acetaminophen, especially with chronic use or doses >4000 mg/day. Monitor liver function. Dependence: Butalbital can cause tolerance and dependence; withdrawal symptoms may occur upon abrupt discontinuation. CNS depression: May impair mental and physical abilities; caution with alcohol or other CNS depressants. Renal impairment: Use with caution in patients with severe renal disease. |
Loading safety data…
| Fetal Monitoring | Monitor fetal growth and development via ultrasound during pregnancy. Assess for signs of neonatal withdrawal after delivery. Monitor maternal liver function if acetaminophen use is prolonged or high dose. Monitor for maternal sedation, hypotension, and respiratory depression. |
| Fertility Effects | No specific data on MICRAININ effects on fertility. However, caffeine may negatively impact female fertility at high doses. Butalbital may affect hormonal balance due to enzyme induction, but clinical significance is unclear. |